BACKGROUND:Daclizumab high-yield process (DAC HYP) is a humanized anti-CD25 monoclonal antibody that inhibits high-affinity interleukin-2 receptor signaling. OBJECTIVE: The objective of this paper is to assess the proportion of DAC HYP- versus placebo-treated patients who were free from disease activity. METHODS: SELECT was a randomized, double-blind, multicenter study of DAC HYP 150 mg or 300 mg, or placebo, administered subcutaneously every four weeks for 52 weeks. In this post-hoc analysis of the SELECT trial, 'disease-activity free' was defined as completion through week 52 without relapses or confirmed three-month disability progression (clinical), with no new/newly enlarging T2-hyperintense lesions and no new gadolinium-enhancing lesions at the week 52 scan (radiological). Primary analyses were based on logistic regression controlling for baseline characteristics. RESULTS: More DAC HYP-treated (39%, n = 156) versus placebo-treated patients (11%, n = 22) were disease-activity free (odds ratio (95% confidence interval), 6.18 (3.71-10.32); p < 0.0001). Furthermore, 77% and 48% of DAC HYP-treated patients were free from clinical or radiological disease activity, respectively, compared with 60% and 18% of placebo-treated patients. CONCLUSION: At one year, DAC HYP resulted in a meaningful increase in the proportion of relapsing-remitting MS patients who were disease-activity free versus placebo.
RCT Entities:
BACKGROUND:Daclizumab high-yield process (DAC HYP) is a humanized anti-CD25 monoclonal antibody that inhibits high-affinity interleukin-2 receptor signaling. OBJECTIVE: The objective of this paper is to assess the proportion of DAC HYP- versus placebo-treated patients who were free from disease activity. METHODS: SELECT was a randomized, double-blind, multicenter study of DAC HYP 150 mg or 300 mg, or placebo, administered subcutaneously every four weeks for 52 weeks. In this post-hoc analysis of the SELECT trial, 'disease-activity free' was defined as completion through week 52 without relapses or confirmed three-month disability progression (clinical), with no new/newly enlarging T2-hyperintense lesions and no new gadolinium-enhancing lesions at the week 52 scan (radiological). Primary analyses were based on logistic regression controlling for baseline characteristics. RESULTS: More DAC HYP-treated (39%, n = 156) versus placebo-treated patients (11%, n = 22) were disease-activity free (odds ratio (95% confidence interval), 6.18 (3.71-10.32); p < 0.0001). Furthermore, 77% and 48% of DAC HYP-treated patients were free from clinical or radiological disease activity, respectively, compared with 60% and 18% of placebo-treated patients. CONCLUSION: At one year, DAC HYP resulted in a meaningful increase in the proportion of relapsing-remitting MSpatients who were disease-activity free versus placebo.
Entities:
Keywords:
Relapsing–remitting multiple sclerosis; clinical endpoints; induction of remission; magnetic resonance imaging; radiological endpoints
Authors: Subhash Tummala; Tarun Singhal; Vinit V Oommen; Gloria Kim; Fariha Khalid; Brian C Healy; Rohit Bakshi Journal: Int J MS Care Date: 2017 May-Jun
Authors: Eva Havrdová; Douglas L Arnold; Amit Bar-Or; Giancarlo Comi; Hans-Peter Hartung; Ludwig Kappos; Fred Lublin; Krzysztof Selmaj; Anthony Traboulsee; Shibeshih Belachew; Iain Bennett; Regine Buffels; Hideki Garren; Jian Han; Laura Julian; Julie Napieralski; Stephen L Hauser; Gavin Giovannoni Journal: Mult Scler J Exp Transl Clin Date: 2018-03-12
Authors: Ludwig Kappos; Nicola De Stefano; Mark S Freedman; Bruce Ac Cree; Ernst-Wilhelm Radue; Till Sprenger; Maria Pia Sormani; Terence Smith; Dieter A Häring; Daniela Piani Meier; Davorka Tomic Journal: Mult Scler Date: 2015-11-19 Impact factor: 6.312